Advertisement

New long-term data on acalabrutinib in mantle cell lymphoma and CLL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma and updated results of an ongoing clinical trial assessing acalabrutinib monotherapy in treatment-naïve patients with chronic lymphocytic leukemia at ASH.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Advertisement
Advertisement